ALKERMES | ALKS - Sales Revenues

Stock Price
31.91
Daily Change
-0.09 -0.28%
Monthly
-5.73%
Yearly
-9.65%
Q1 Forecast
30.94

ALKERMES reported $394.2M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
ALKERMES USD 394.2M 3.5M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Coherus Biosciences USD 7.6M 46.54M Mar/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Heron Therapeutics USD 32.81M 3.21M Sep/2024
Ionis Pharmaceuticals USD 157M 295M Sep/2025
J&J USD 24.6B 610M Dec/2025
Merck USD 16.4B 880M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 24.12M 635K Sep/2024
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Otsuka Holdings JPY 650.15B 12.17B Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025